Pharmaceuticals News and Research

RSS

State abortion clinic restrictions could impact women's health care access

Stateline reports that abortion opponents are advancing new clinic standards that may be impossible to meet. Abortion rights supporters fear these rules could force many clinics to close, making it more difficult for some women to get a broad array of health care services.

25 Jul 2013

Most U.S. physicians prioritize obligations to patients' best interests over health care cost concerns

A new study of attitudes about health care costs reveals that an overwhelming majority of U.S. physicians feel a responsibility to address costs, but prioritize their obligations to patients' best interests over cost concerns. Results of the random survey of 2,500 U.S. physicians are published in this week's Journal of the American Medical Association.

25 Jul 2013

Ligand Pharmaceuticals, Ethicor Pharma sign license agreement for lasofoxifene

Ligand Pharmaceuticals Incorporated announces the signing of a license agreement with Ethicor Pharma Ltd. for the manufacture and distribution of the oral formulation of lasofoxifene in the European Economic Area, Switzerland and the Indian Subcontinent.

24 Jul 2013

Mylan Pharmaceuticals agrees to resolve patent litigation related to Erlotinib Hydrochloride Tablets

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has entered into a settlement agreement with OSI, Pfizer and Genentech that will resolve patent litigation related to Erlotinib Hydrochloride Tablets, 25 mg, 100 mg and 150 mg.

24 Jul 2013

First Edition: July 24, 2013

Today's headlines include reports about efforts to both advance and undo the health law's implementation.

24 Jul 2013

OracleBio to highlight Oncology image analysis expertise at Tumor Models conference

OracleBio, providers of high precision digital image analysis services for detailed quantification of histological marker staining within cells and tissues, is pleased to announce it will be a principal sponsor of the forthcoming Tumor Models conference to be held in Boston, MA on the 23-25th July.

24 Jul 2013

Child cancer survival: an interview with Prof Kathy Pritchard-Jones, University College London

Back in the early 1960s, just before chemotherapy really started to be used, only about 30% of children survived cancer. That was mainly because they had cancers that were amenable to surgery.

24 Jul 2013

FMC acquires all shares of Epax for $345 million

FMC Corporation today announced that it has acquired all of the shares of Epax Nutra Holding III AS (Norway) and Epax UK Holding III AS (United Kingdom) (together, "Epax"), a leading manufacturer of high purity, premium grade Omega-3 fatty acid concentrates that are used in nutraceuticals, pharmaceuticals and food.

24 Jul 2013

Inovio plans to advance synthetic hTERT cancer vaccine into clinical trials in 2014

Inovio Pharmaceuticals, Inc. announced today that in a preclinical study with two animal models, Inovio's hTERT (human telomerase reverse transcriptase) DNA cancer vaccine administered with Inovio's CELLECTRA adaptive electroporation delivery technology generated robust and broad immune responses, broke the immune system's tolerance to its self-antigens, induced T-cells with a tumor-killing function, and increased the rate of survival.

24 Jul 2013

Scientists reveal new images of how white blood immune cells attack tumours, viral infections

Scientists from The University of Manchester have revealed new images which provide the clearest picture yet of how white blood immune cells attack viral infections and tumours.

From The University of Manchester 24 Jul 2013

FDA takes action to remove illegal diabetes products from market

The U.S. Food and Drug Administration is taking action to remove from the market illegal products, including some labeled as dietary supplements, that claim to mitigate, treat, cure or prevent diabetes and related complications.

24 Jul 2013

New approaches provide lifetime support for individuals with ASD

More than 300 parents, healthcare providers and educators from across the U.S. and around the world, will come together July 26 through July 27, 2013 at the second annual national conference for families and professionals, "Treating the Whole Person with Autism: Care Across the Lifespan." The conference — sponsored by Autism Speaks, the world's leading autism and advocacy organization, with our educational partners at Nationwide Children's Hospital, Ohio State University Wexner Medical Center, the U.S.

24 Jul 2013

NYCEDC declares Innovate Health Tech NYC winners

New York City Economic Development Corporation today announced the winners of Innovate Health Tech NYC, a competition designed to promote innovation within New York City's health technology sector.

23 Jul 2013

Serum Institute of India secures license to patents, technologies related to tuberculosis vaccine

Hopes are high for a new and improved tuberculosis vaccine: Serum Institute of India is planning on taking a promising vaccine - originally developed in Germany - and introducing it into the clinical setting.

23 Jul 2013

Results of post-mortem brain tissue study using Navidea's NAV4694 imaging agent presented at AAIC 2013

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that researchers at McGill Center for Studies in Aging, Douglas Research Institute and Montreal Neurological Institute presented results of a post-mortem brain tissue study using Navidea's investigational Fluorine-18 labeled β-amyloid imaging agent, NAV4694, during the Alzheimer's Association International Conference in Boston, MA.

23 Jul 2013

Imprimis to begin IRB-approved Impracor Phase III trial for acute pain associated with OA of the knee

Imprimis Pharmaceuticals, Inc., which is focused on the commercialization of compounded drug formulations utilizing the FDA 505(b)(2) development pathway, today announced it has received IRB approval for its Phase III clinical trial protocol of its lead product candidate, Impracor.

23 Jul 2013

AMRI receives a Form 483 from the FDA for Burlington pharmaceutical manufacturing facility

As previously disclosed, Albany Molecular Research, Inc. ("AMRI" or "the "Company") (NASDAQ: AMRI) received a warning letter, dated August 17, 2010, from the U.S. Food and Drug Administration (FDA) in connection with the FDA's inspection of the Company's pharmaceutical manufacturing facility located in Burlington, Massachusetts.

23 Jul 2013

p53 and cancer research: an interview with Professor Sir David Lane, Scientific Director of the Ludwig Institute for Cancer Research

P53 is a tumor suppressor gene. The gene encodes for a protein that monitors the state of the cell. If something goes wrong, it stops the cell from dividing or causes the cell to commit suicide. I call it the “guardian of the genome” as it is the molecule that seems to keep cells normal. It is one of our big defenses against cancer.

22 Jul 2013

Ligand, Azure Biotech sign global license agreement for development of lasofoxifene

Ligand Pharmaceuticals Incorporated announces the signing of a global license agreement with Azure Biotech for the development of a novel formulation of lasofoxifene targeting an underserved market in women's health.

22 Jul 2013

BioCryst completes BCX4161 Phase 1 clinical trial for treatment of hereditary angioedema

BioCryst Pharmaceuticals, Inc. announced that the randomized, placebo-controlled, Phase 1 clinical trial of orally-administered BCX4161 in healthy volunteers successfully met all of its objectives.

22 Jul 2013

Pharmaceuticals News and Research

State abortion clinic restrictions could impact women's health care access

Most U.S. physicians prioritize obligations to patients' best interests over health care cost concerns

Ligand Pharmaceuticals, Ethicor Pharma sign license agreement for lasofoxifene

Mylan Pharmaceuticals agrees to resolve patent litigation related to Erlotinib Hydrochloride Tablets

First Edition: July 24, 2013

OracleBio to highlight Oncology image analysis expertise at Tumor Models conference

Child cancer survival: an interview with Prof Kathy Pritchard-Jones, University College London

FMC acquires all shares of Epax for $345 million

Inovio plans to advance synthetic hTERT cancer vaccine into clinical trials in 2014

Scientists reveal new images of how white blood immune cells attack tumours, viral infections

FDA takes action to remove illegal diabetes products from market

New approaches provide lifetime support for individuals with ASD

NYCEDC declares Innovate Health Tech NYC winners

Serum Institute of India secures license to patents, technologies related to tuberculosis vaccine

Results of post-mortem brain tissue study using Navidea's NAV4694 imaging agent presented at AAIC 2013

Imprimis to begin IRB-approved Impracor Phase III trial for acute pain associated with OA of the knee

AMRI receives a Form 483 from the FDA for Burlington pharmaceutical manufacturing facility

p53 and cancer research: an interview with Professor Sir David Lane, Scientific Director of the Ludwig Institute for Cancer Research

Ligand, Azure Biotech sign global license agreement for development of lasofoxifene

BioCryst completes BCX4161 Phase 1 clinical trial for treatment of hereditary angioedema

Ultimate guide to the essential tools for the characterization of proteins, polymers and nanoparticles eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence